division of infectious diseases Archives
HERO-TOGETHER study seeks health care workers who receive COVID-19 vaccine
Dec. 21, 2020—Health care workers, who have been disproportionately affected by the COVID-19 pandemic, will be the first tier of Vanderbilt University Medical Center employees to receive vaccine to prevent SARS-CoV-2 infection.
Study details early events of inflammatory response
Dec. 10, 2020—Vanderbilt University Medical Center investigators have identified a key molecular player in the early events of the inflammatory response to infection. The findings suggest new therapeutic possibilities for enhancing the inflammatory response to protect against pathogens and for blocking inflammation gone awry in diseases like arthritis and atherosclerosis.
THA honors VUMC efforts in remdesivir distribution
Oct. 14, 2020—A team of pharmacists and physicians from Vanderbilt University Medical Center that this spring took on statewide distribution of remdesivir, an urgently needed investigational drug for severely ill patients hospitalized with COVID-19, has received the President’s Award from the Tennessee Hospital Association (THA).
Genes spell penicillin allergy risk
Oct. 1, 2020—Studies using large DNA biobanks revealed genetic variants associated with penicillin allergy, the most common type of drug-induced allergic reaction.
American Airlines boosts travelers’ peace of mind with VUMC expertise
Jun. 26, 2020—American Airlines has created a new Travel Health Advisory Panel that includes Vanderbilt University Medical Center infectious disease experts to advise on health and cleaning matters as travelers return over the summer.
Target trials support drug safety in pregnant patients
May. 27, 2020—Out of concern for fetal safety, pregnant people have typically been excluded from drug trials. And when human health is on the line, drug studies assessing fetal safety in animal models may be viewed as far from definitive.
Deadline extended for transplant infectious diseases fellowship
Jan. 9, 2020—The Division of Infectious Diseases at Vanderbilt University Medical Center is seeking applicants for its new Transplant and Immunocompromised Host Infectious Diseases Fellowship Program.
Applications sought for Transplant Infectious Diseases/Immunocompromised Host Fellowship Program
Dec. 16, 2019—The Division of Infectious Diseases is seeking applicants for its new Transplant Infectious Diseases/Immunocompromised Host (TID/ICH) Fellowship Program.
Treating C. diff: new purpose for an old drug?
Sep. 24, 2019—An inexpensive generic drug once used to prevent gastrointestinal ulcers in people taking daily NSAIDs protects against C. diff infection in mice.
Effort seeks to improve safety of drugs given during pregnancy
Jul. 18, 2019—A 19-year-old student is leading a multi-institutional collaboration to identify drugs that can be prescribed safely to pregnant women without harming the fetus.
Vanderbilt team shows how stomach bug can trigger cancer
Jul. 11, 2019—Researchers at Vanderbilt University and the University of Michigan in Ann Arbor have obtained the first high-resolution image of a molecular “machine” used by the insidious stomach bug Helicobacter pylori (H. pylori) to inject a cancer-causing protein into the stomach lining.
Pain relievers a risk for C. diff?
Jan. 17, 2019—A link between anti-inflammatory drugs such as ibuprofen and C. diff infection suggests caution against overusing such drugs in patients at high risk for infection.
